Latest On Dr. Reddy's Laboratories Limited (RDY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 14:01 EST | News | Dr Reddy's Laboratories Ltd (RDY) Q4 2023 Earnings Call Transcript | N/A |  |
| 2023-05-10 23:46 EST | News | Dr. Reddy's GAAP EPS of $0.70, revenue of $766M beats by $8.32M | N/A | |
| 2023-05-05 08:37 EST | News | Dr. Reddy's launches generic version of Astellas' Lexiscan in US | N/A | |
| 2023-04-21 15:46 EST | News | Dr. Reddy's launches generic version of hypertension drug Remodulin in US | N/A | |
| 2023-04-20 16:44 EST | News | Aditxt stock rises ~10% on plans to buy 50% stake in Global Response Aid from Cellvera | N/A | |
| 2023-02-27 23:24 EST | News | Dr. Reddy's to acquire U.S. generic portfolio of Mayne Pharma | N/A | |
| 2023-02-16 08:17 EST | News | Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy | N/A | |
| 2023-01-26 01:34 EST | News | Dr. Reddy's Laboratories Limited (RDY) Q3 2023 Earnings Call Transcript | N/A | |
| 2023-01-25 11:25 EST | News | Dr. Reddy's GAAP EPS of $0.91, revenue of $818M | N/A | |
| 2023-01-25 11:25 EST | News | Dr. Reddy's Laboratories Limited 2023 Q3 - Results - Earnings Call Presentation | N/A | |
| 2023-01-20 13:11 EST | News | Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed | N/A | |
| 2022-11-06 20:23 EST | News | Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue | N/A | |
| 2022-10-29 00:52 EST | News | Dr. Reddy's Laboratories Limited (RDY) Q2 2023 Earnings Call Transcript | N/A | |
| 2022-07-31 01:42 EST | News | Dr. Reddy's Laboratories Limited's (RDY) CEO Erez Israeli on Q1 2023 Results - Earnings Call Transcript | N/A | |
| 2022-07-31 01:42 EST | News | Dr. Reddy's Laboratories: Multiple Drug Launches To Drive Significant Growth | N/A | |
| 2022-07-28 18:03 EST | News | Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M | N/A | |
| 2022-07-28 03:28 EST | News | Dr. Reddy's Q1 2023 Earnings Preview | N/A | |
| 2022-07-27 13:17 EST | News | Dr. Reddy's launches generic of Takeda's cancer drug Velcade in US | N/A | |
| 2022-07-22 09:15 EST | News | Dr. Reddy's launches generic drugs for allergies in US | N/A | |
| 2022-07-05 06:41 EST | News | Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases | N/A | |
| 2022-06-24 18:38 EST | News | Eton Pharmaceuticals sells hospital products to Dr. Reddy’s for up to $50M | N/A | |
| 2022-06-14 09:38 EST | News | Dr. Reddy's launches generic version of Bayer's kidney/liver cancer drug Nexavar in US | N/A | |
| 2022-05-27 13:36 EST | News | Dr. Reddy's launches generic version of cancer drug Alimta in the U.S. | N/A | |
| 2022-05-20 09:46 EST | News | Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q4 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-19 13:37 EST | News | Dr. Reddy's GAAP EPS of $0.07, revenue of $717M beats by $54.69M | N/A | |
| 2022-04-05 18:32 EST | News | Dr. Reddy’s launches methylprednisolone sodium succinate for injection in US | N/A | |
| 2022-04-01 16:23 EST | News | Novartis agrees to sell heart disease drug, Cidmus to Dr. Reddy's in India | N/A | |
| 2022-02-03 21:49 EST | News | Dr. Reddy's to acquire German medical cannabis company Nimbus Health | N/A | |
| 2022-01-28 17:45 EST | News | Dr. Reddy's GAAP EPS of $0.57, revenue of $715M | N/A | |
| 2022-01-28 17:44 EST | News | Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2022 Results - Earnings Call Transcript | N/A | |
| 2022-01-28 00:49 EST | News | Dr. Reddy's FQ3 2022 Earnings Preview | N/A | |
| 2021-12-10 07:10 EST | News | Dr. Reddy's launches Venlafaxine ER tablets in U.S. | N/A | |
| 2021-12-09 12:53 EST | News | Dr. Reddy's launches Valsartan tablets U.S. | N/A | |
| 2021-12-09 12:53 EST | News | Dr. Reddy’s, Prestige Bio team up to commercialize trastuzumab biosimilar in Latin America, Southeast Asia | N/A | |
| 2021-11-15 17:26 EST | News | Dr. Reddy's mulls production of Pfizer COVID-19 pill | N/A | |
| 2021-10-29 10:54 EST | News | Dr. Reddy’s launches generic version of low blood pressure drug Akovaz in US | N/A | |
| 2021-10-19 23:05 EST | News | FDA approves Dr. Reddy’s Laboratories' generic version of Revlimid | N/A | |
| 2021-09-08 01:06 EST | News | Citius Pharmaceuticals acquires license for lymphoma treatment E7777 from Dr. Reddy's | N/A | |
| 2021-09-02 11:25 EST | News | Dr. Reddy's launches generic Revlimid in Canada | N/A | |
| 2021-08-03 23:38 EST | News | Dr. Reddy’s re-launches OTC Naproxen Sodium Tablets in U.S. | N/A | |
| 2021-07-27 21:01 EST | News | Dr. Reddy's to record sharpest one-day loss in five years as Credit Suisse cuts rating on Q1 financials | N/A | |
| 2021-07-27 21:01 EST | News | Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q1 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-22 13:48 EST | News | Dr. Reddy's in talks to bring single-dose Sputnik Light vaccine in India | N/A | |
| 2021-07-22 13:48 EST | News | Amarin falls after Supreme Court rejection on Vascepa (updated) | N/A | |
| 2021-07-22 13:48 EST | News | Dr. Reddy's launches Icosapent Ethyl Capsules, 1 gram in U.S. | N/A | |
| 2021-07-22 13:47 EST | News | Merck joined by Indian drugmakers to conduct domestic trial for COVID-19 therapy | N/A | |
| 2021-07-22 13:47 EST | News | Journey Medical and Dr. Reddy’s team up to develop skin disease treatment | N/A | |
| 2021-07-08 06:04 EST | Dividend | A dividend of $0.34 has been announced on Jun 16, 2021. It will be paid Nov 30, -0001 with an ex-dividend date of Jul 8, 2021. | Neutral | |
| 2021-04-13 06:26 EST | News | Dr. Reddy's gets emergency use authorization for Sputnik V in India | N/A | |
| 2021-04-07 07:44 EST | News | Dr. Reddy's launches generic Sapropterin Dihydrochloride powder in U.S. | N/A | |
About Dr. Reddy's Laboratories Limited (RDY):
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.
General
- Name Dr. Reddy's Laboratories Limited
- Symbol RDY
- Type Common Stock
- Exchange NYSE
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 21,650
- Last Split Factor2:1
- Last Split Date2006-09-07
- Fiscal Year EndMarch
- IPO Date2001-04-11
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.drreddys.com
View More
Valuation
- Trailing PE 41.3
- Forward PE 25.51
- Price/Sales (Trailing 12 Mt.) 3.86
- Price/Book (Most Recent Quarter) 4.24
- Enterprise Value Revenue 0.05
- Enterprise Value EBITDA 0.25
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $1.64
- Next Year EPS Estimate $2.87
- Next Quarter EPS Estimate $0.51
- Profit Margin 11%
- Return on Assets 9%
- Return on Equity 13%
- Earnings Per Share $1.40
- Revenue Per Share $0
- Gross Profit 94.01 billion
- Quarterly Earnings Growth 12.5%
View More
Highlights
- Market Capitalization 9.68 billion
- PEG Ratio 3.08
- Analyst Target Price $72.5
- Book Value Per Share $11.58
View More
Share Statistics
- Shares Outstanding 165.94 million
- Shares Float 117.59 million
- % Held by Insiders 1%
- % Held by Institutions 13.67%
- Shares Short 1.28 million
- Shares Short Prior Month 1.09 million
- Short Ratio 4.78
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta -0.02
- 52 Week High $73.39
- 52 Week Low $34.68
- 50 Day Moving Average 62.37
- 200 Day Moving Average 65.95
View More
Dividends
- Forward Annual Dividend Rate $0.33
- Forward Annual Dividend Yield 0.56%
- Payout Ratio 19%
- Dividend Date 2020-08-17
- ExDividend Date 2020-07-10
- Dividend Per Share $0.29
- Dividend Yield 0.67%
View More
Dr. Reddy's Laboratories Limited (RDY) Dividend Calendar:
Dr. Reddy's Laboratories Limited pays an annual dividend of $0.33 per share, with a dividend yield of 0.67%.
RDY's last dividend payment was made to shareholders on August 17, 2020.
Dr. Reddy's Laboratories Limited pays out 19% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Dr. Reddy's Laboratories Limited (RDY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-01-29 | $N/A | $0.05 | $0.52 | -90.25% |
| 2020-09-30 | 2020-10-28 | $48.97 billion | $0.62 | $0.48 | 27.95% |
| 2020-06-30 | 2020-07-29 | $44.18 billion | $0.46 | $0.52 | -11.33% |
| 2020-03-31 | 2020-06-09 | $N/A | $0.61 | $0.49 | 24.59% |
| 2019-12-31 | 2020-01-27 | $614.36 million | $0.63 | $0.51 | 24.7% |
| 2019-09-30 | 2019-11-01 | $679.58 million | $0.94 | $0.49 | 90.87% |
| 2019-06-30 | 2019-07-29 | $557.96 million | $0.58 | $0.37 | 57.11% |
| 2019-03-31 | 2019-05-17 | $580.39 million | $0.37 | ||
| 2018-12-31 | 2019-02-01 | $553.4 million | $0.41 | ||
| 2018-09-30 | 2018-10-26 | $520.78 million | $0.43 | ||
| 2018-06-30 | 2018-07-26 | $541.43 million | $0.41 | ||
| 2018-03-31 | 2018-05-22 | $542.75 million | $0.28 | ||
| 2017-12-31 | 2018-01-25 | $620.47 million | $0.31 | ||
| 2017-09-30 | 2017-11-01 | $537.69 million | $0.27 | ||
| 2017-06-30 | 2017-07-27 | $513.14 million | $0.06 | ||
| 2017-03-31 | 2017-05-12 | $617.53 million | $0.28 | ||
| 2016-12-31 | 2017-02-10 | $522.05 million | $0.42 | ||
| 2016-09-30 | 2016-10-26 | $541.43 million | $0.27 | ||
| 2016-06-30 | 2016-07-26 | $475.81 million | $0.11 | ||
| 2016-03-31 | 2016-05-12 | $565.37 million | $0.06 | ||
| 2015-12-31 | 2016-02-09 | $587.14 million | $0.51 | ||
| 2015-09-30 | 2015-10-29 | $591.76 million | $0.65 | ||
| 2015-06-30 | 2015-07-31 | $590.94 million | $0.57 | ||
| 2015-03-31 | 2015-05-12 | $641.5 million | $0.49 | ||
| 2014-12-31 | 2015-01-29 | $589.24 million | $0.54 | ||
| 2014-09-30 | 2014-10-29 | $561.85 million | $0.55 | ||
| 2014-06-30 | 2014-07-30 | $585.66 million | $0.54 | ||
| 2014-03-31 | 2014-05-13 | $630.47 million | $0.46 | ||
| 2013-12-31 | 2014-02-11 | $581.25 million | $0.54 | $0.45 | 20% |
| 2013-09-30 | 2013-10-31 | $513.14 million | $0.65 | $0.46 | 41.3% |
| 2013-06-30 | 2013-07-30 | $477.97 million | $0.36 | $0.43 | -16.28% |
| 2013-03-31 | 2013-05-14 | $608.87 million | $0.60 | $0.54 | 11.11% |
| 2012-12-31 | 2013-02-14 | $486.03 million | $0.40 | $0.55 | -27.27% |
| 2012-09-30 | 2012-10-30 | $567.28 million | $0.44 | ||
| 2012-06-30 | 2012-07-20 | $457.19 million | $0.36 | ||
| 2012-03-31 | 2012-05-11 | $569.55 million | $0.40 | ||
| 2011-12-31 | 2012-02-06 | $457.72 million | $0.59 | ||
| 2011-09-30 | 2011-10-25 | $422.01 million | $0.39 | ||
| 2011-06-30 | 2011-07-20 | $443.66 million | $0.35 | ||
| 2011-03-31 | 2011-05-13 | $452.03 million | $0.43 | ||
| 2010-12-31 | 2011-01-25 | $419.5 million | $0.36 | ||
| 2010-09-30 | 2010-10-23 | $434.81 million | $0.37 | ||
| 2010-06-30 | 2010-07-22 | $362.66 million | $0.27 | ||
| 2010-03-31 | 2010-05-06 | $395.77 million | $0.14 | ||
| 2009-12-31 | 2010-01-20 | $400.45 million | -$0.30 | ||
| 2009-09-30 | 2009-10-23 | $379.2 million | $0.29 | ||
| 2009-06-30 | 2009-07-21 | $381 million | $0.29 | ||
| 2009-03-31 | 2009-05-18 | $344.07 million | -$1.48 | ||
| 2008-12-31 | 2009-01-23 | $349.55 million | $0.19 | ||
| 2008-09-30 | 2008-10-23 | $321.45 million | $0.12 | ||
| 2008-06-30 | 2008-07-21 | $350 million | $0.13 | ||
| 2008-03-31 | 2008-05-20 | $316.91 million | $0.12 | ||
| 2007-12-31 | 2008-01-25 | $317.91 million | $0.09 | ||
| 2007-09-30 | 2007-10-24 | $319.4 million | $0.16 | ||
| 2007-06-30 | 2007-07-23 | $295.3 million | $0.27 | ||
| 2007-03-31 | 2007-05-18 | $387.63 million | $0.63 | ||
| 2006-12-31 | 2007-01-22 | $380.85 million | $0.15 | ||
| 2006-09-30 | 2006-10-27 | $435.56 million | $0.41 | ||
| 2006-06-30 | 2006-07-27 | $306.29 million | $0.18 | ||
| 2006-03-31 | 2006-05-31 | $159.91 million | -$0.06 | ||
| 2005-12-31 | 2006-01-24 | $126.01 million | $0.09 | ||
| 2005-09-30 | 2005-10-29 | $131.24 million | $0.13 | $0.06 | 116.67% |
| 2005-06-30 | 2005-07-26 | $128.41 million | $0.05 | $0.06 | -16.67% |
| 2005-03-31 | 2005-05-06 | $94.66 million | -$0.04 | ||
| 2004-12-31 | 2005-02-01 | $122.7 million | -$0.01 | ||
| 2004-09-30 | 2004-10-27 | $117.98 million | $0.07 | ||
| 2004-06-30 | 2004-07-28 | $111.07 million | $0.02 | ||
| 2004-03-31 | 2004-05-28 | $126.23 million | $0.03 | ||
| 2003-09-30 | 2003-10-28 | $118.85 million | $0.13 | ||
| 2003-06-30 | 2003-07-31 | $103.7 million | $0.12 | ||
| 2003-03-31 | 2003-03-31 | $91.62 million | $0.08 | ||
| 2002-12-31 | 2002-12-31 | $92.21 million | $0.09 | ||
| 2002-09-30 | 2002-09-30 | $102.79 million | $0.14 |
Dr. Reddy's Laboratories Limited (RDY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Dr. Reddy's Laboratories Limited (RDY) Chart:
Dr. Reddy's Laboratories Limited (RDY) News:
Below you will find a list of latest news for Dr. Reddy's Laboratories Limited (RDY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Dr. Reddy's Laboratories Limited (RDY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 40 | 0 | CALL | 0 | 0 | 127.25 | TRUE | 0 | 0 |
| 2024-05-17 | 45 | 0 | CALL | 0 | 0 | 103.2 | TRUE | 0 | 0 |
| 2024-05-17 | 50 | 0 | CALL | 0 | 0 | 88.53 | TRUE | 0 | 0 |
| 2024-05-17 | 55 | 0 | CALL | 0 | 0 | 77.09 | TRUE | 0 | 0 |
| 2024-05-17 | 60 | 0 | CALL | 0 | 0 | 56.23 | TRUE | 0 | 0 |
| 2024-05-17 | 65 | 0 | CALL | 0 | 0 | 31.79 | TRUE | 0 | 0 |
| 2024-05-17 | 70 | 3 | CALL | 0 | 1 | 32.53 | TRUE | 0 | 0 |
| 2024-05-17 | 75 | 1.25 | CALL | 0 | 8 | 40.43 | FALSE | 0 | 0 |
| 2024-05-17 | 80 | 0.15 | CALL | 1 | 2 | 28.82 | FALSE | -0.3 | -0.67 |
| 2024-05-17 | 85 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 90 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 95 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 100 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 105 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 110 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 115 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 40 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 45 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 50 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 55 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 60 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 65 | 0.85 | PUT | 0 | 1 | 75.09 | FALSE | 0 | 0 |
| 2024-05-17 | 70 | 1.25 | PUT | 0 | 26 | 49.11 | FALSE | 0 | 0 |
| 2024-05-17 | 75 | 4.5 | PUT | 0 | 0 | 30.06 | TRUE | 0 | 0 |
| 2024-05-17 | 80 | 9.08 | PUT | 0 | 0 | 27.63 | TRUE | 0 | 0 |
| 2024-05-17 | 85 | 0 | PUT | 0 | 0 | 94.66 | TRUE | 0 | 0 |
| 2024-05-17 | 90 | 0 | PUT | 0 | 0 | 53.34 | TRUE | 0 | 0 |
| 2024-05-17 | 95 | 0 | PUT | 0 | 0 | 63.33 | TRUE | 0 | 0 |
| 2024-05-17 | 100 | 0 | PUT | 0 | 0 | 67.97 | TRUE | 0 | 0 |
| 2024-05-17 | 105 | 0 | PUT | 0 | 0 | 149.55 | TRUE | 0 | 0 |
| 2024-05-17 | 110 | 0 | PUT | 0 | 0 | 89.38 | TRUE | 0 | 0 |
| 2024-05-17 | 115 | 0 | PUT | 0 | 0 | 172.85 | TRUE | 0 | 0 |
| 2024-06-21 | 35 | 0 | CALL | 0 | 0 | 110.03 | TRUE | 0 | 0 |
| 2024-06-21 | 40 | 0 | CALL | 0 | 0 | 90.51 | TRUE | 0 | 0 |
| 2024-06-21 | 45 | 0 | CALL | 0 | 0 | 77.02 | TRUE | 0 | 0 |
| 2024-06-21 | 50 | 0 | CALL | 0 | 0 | 61.1 | TRUE | 0 | 0 |
| 2024-06-21 | 55 | 20.1 | CALL | 0 | 0 | 45.17 | TRUE | 0 | 0 |
| 2024-06-21 | 60 | 17.1 | CALL | 0 | 17 | 42.27 | TRUE | 0 | 0 |
| 2024-06-21 | 65 | 7.7 | CALL | 0 | 5 | 34.96 | TRUE | 0 | 0 |
| 2024-06-21 | 70 | 5.91 | CALL | 0 | 55 | 30.43 | TRUE | 0 | 0 |
| 2024-06-21 | 75 | 1.65 | CALL | 0 | 37 | 28.31 | FALSE | 0 | 0 |
| 2024-06-21 | 80 | 0.7 | CALL | 0 | 21 | 36.64 | FALSE | 0 | 0 |
| 2024-06-21 | 85 | 1.65 | CALL | 0 | 44 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 90 | 0.95 | CALL | 0 | 19 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 95 | 0.15 | CALL | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 100 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 105 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 110 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 115 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 35 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 40 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 45 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 50 | 0.7 | PUT | 0 | 12 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 55 | 0.25 | PUT | 0 | 9 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 60 | 1.25 | PUT | 0 | 24 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 65 | 0.95 | PUT | 0 | 4 | 38.92 | FALSE | 0 | 0 |
| 2024-06-21 | 70 | 2.1 | PUT | 0 | 52 | 35.62 | FALSE | 0 | 0 |
| 2024-06-21 | 75 | 5 | PUT | 0 | 1 | 18.96 | TRUE | 0 | 0 |
| 2024-06-21 | 80 | 0 | PUT | 0 | 0 | 21.6 | TRUE | 0 | 0 |
| 2024-06-21 | 85 | 0 | PUT | 0 | 0 | 28.13 | TRUE | 0 | 0 |
| 2024-06-21 | 90 | 0 | PUT | 0 | 0 | 35.37 | TRUE | 0 | 0 |
| 2024-06-21 | 95 | 0 | PUT | 0 | 0 | 81.08 | TRUE | 0 | 0 |
| 2024-06-21 | 100 | 0 | PUT | 0 | 0 | 89.49 | TRUE | 0 | 0 |
| 2024-06-21 | 105 | 0 | PUT | 0 | 0 | 97.24 | TRUE | 0 | 0 |
| 2024-06-21 | 110 | 0 | PUT | 0 | 0 | 59.53 | TRUE | 0 | 0 |
| 2024-06-21 | 115 | 0 | PUT | 0 | 0 | 111.13 | TRUE | 0 | 0 |
| 2024-09-20 | 35 | 0 | CALL | 0 | 0 | 70 | TRUE | 0 | 0 |
| 2024-09-20 | 40 | 0 | CALL | 0 | 0 | 60.25 | TRUE | 0 | 0 |
| 2024-09-20 | 45 | 0 | CALL | 0 | 0 | 53.97 | TRUE | 0 | 0 |
| 2024-09-20 | 50 | 0 | CALL | 0 | 0 | 43.24 | TRUE | 0 | 0 |
| 2024-09-20 | 55 | 0 | CALL | 0 | 0 | 38.08 | TRUE | 0 | 0 |
| 2024-09-20 | 60 | 0 | CALL | 0 | 0 | 35.87 | TRUE | 0 | 0 |
| 2024-09-20 | 65 | 0 | CALL | 0 | 0 | 30.35 | TRUE | 0 | 0 |
| 2024-09-20 | 70 | 5.3 | CALL | 0 | 3 | 27.23 | TRUE | 0 | 0 |
| 2024-09-20 | 75 | 2.95 | CALL | 0 | 5 | 25.92 | FALSE | 0 | 0 |
| 2024-09-20 | 80 | 1.7 | CALL | 0 | 106 | 29.97 | FALSE | 0 | 0 |
| 2024-09-20 | 85 | 1.35 | CALL | 0 | 11 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 90 | 0.75 | CALL | 0 | 2 | 36.99 | FALSE | 0 | 0 |
| 2024-09-20 | 95 | 0.45 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 100 | 0.7 | CALL | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 105 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 110 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 115 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 35 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 40 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 45 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 50 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 55 | 0.3 | PUT | 0 | 1 | 27.47 | FALSE | 0 | 0 |
| 2024-09-20 | 60 | 0.85 | PUT | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 65 | 1.55 | PUT | 0 | 10 | 30.99 | FALSE | 0 | 0 |
| 2024-09-20 | 70 | 3.3 | PUT | 0 | 12 | 24.88 | FALSE | 0 | 0 |
| 2024-09-20 | 75 | 3.45 | PUT | 0 | 1 | 16.81 | TRUE | 0 | 0 |
| 2024-09-20 | 80 | 0 | PUT | 0 | 0 | 20.69 | TRUE | 0 | 0 |
| 2024-09-20 | 85 | 0 | PUT | 0 | 0 | 41.61 | TRUE | 0 | 0 |
| 2024-09-20 | 90 | 0 | PUT | 0 | 0 | 26.12 | TRUE | 0 | 0 |
| 2024-09-20 | 95 | 0 | PUT | 0 | 0 | 53.94 | TRUE | 0 | 0 |
| 2024-09-20 | 100 | 0 | PUT | 0 | 0 | 59.54 | TRUE | 0 | 0 |
| 2024-09-20 | 105 | 0 | PUT | 0 | 0 | 40.96 | TRUE | 0 | 0 |
| 2024-09-20 | 110 | 0 | PUT | 0 | 0 | 69.48 | TRUE | 0 | 0 |
| 2024-09-20 | 115 | 0 | PUT | 0 | 0 | 73.97 | TRUE | 0 | 0 |
| 2024-12-20 | 40 | 0 | CALL | 0 | 0 | 57.95 | TRUE | 0 | 0 |
| 2024-12-20 | 45 | 0 | CALL | 0 | 0 | 47.36 | TRUE | 0 | 0 |
| 2024-12-20 | 50 | 0 | CALL | 0 | 0 | 42.51 | TRUE | 0 | 0 |
| 2024-12-20 | 55 | 0 | CALL | 0 | 0 | 37.09 | TRUE | 0 | 0 |
| 2024-12-20 | 60 | 0 | CALL | 0 | 0 | 31.56 | TRUE | 0 | 0 |
| 2024-12-20 | 65 | 0 | CALL | 0 | 0 | 30.24 | TRUE | 0 | 0 |
| 2024-12-20 | 70 | 6.7 | CALL | 0 | 1 | 27.2 | TRUE | 0 | 0 |
| 2024-12-20 | 75 | 4.3 | CALL | 0 | 10 | 25.49 | FALSE | 0 | 0 |
| 2024-12-20 | 80 | 2.5 | CALL | 0 | 1 | 24.09 | FALSE | 0 | 0 |
| 2024-12-20 | 85 | 1.65 | CALL | 0 | 1 | 27.48 | FALSE | 0 | 0 |
| 2024-12-20 | 90 | 1.35 | CALL | 0 | 2 | 32.73 | FALSE | 0 | 0 |
| 2024-12-20 | 95 | 1.05 | CALL | 1 | 0 | 27.6 | FALSE | 1.05 | 0 |
| 2024-12-20 | 100 | 0.8 | CALL | 1 | 0 | 28.94 | FALSE | 0.8 | 0 |
| 2024-12-20 | 105 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 40 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 45 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 50 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 55 | 0 | PUT | 0 | 0 | 42.63 | FALSE | 0 | 0 |
| 2024-12-20 | 60 | 0 | PUT | 0 | 0 | 33.19 | FALSE | 0 | 0 |
| 2024-12-20 | 65 | 2 | PUT | 0 | 1 | 25.34 | FALSE | 0 | 0 |
| 2024-12-20 | 70 | 0 | PUT | 0 | 0 | 23.04 | FALSE | 0 | 0 |
| 2024-12-20 | 75 | 0 | PUT | 0 | 0 | 23.08 | TRUE | 0 | 0 |
| 2024-12-20 | 80 | 0 | PUT | 0 | 0 | 21.34 | TRUE | 0 | 0 |
| 2024-12-20 | 85 | 0 | PUT | 0 | 0 | 22.31 | TRUE | 0 | 0 |
| 2024-12-20 | 90 | 0 | PUT | 0 | 0 | 39.68 | TRUE | 0 | 0 |
| 2024-12-20 | 95 | 0 | PUT | 0 | 0 | 44.75 | TRUE | 0 | 0 |
| 2024-12-20 | 100 | 0 | PUT | 0 | 0 | 49.4 | TRUE | 0 | 0 |
| 2024-12-20 | 105 | 0 | PUT | 0 | 0 | 53.69 | TRUE | 0 | 0 |
Latest RDY Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 70 | $54.38 |
| Jun 13, 2022 7:59 PM EST | 57 | $54.37 |
| Jun 13, 2022 7:59 PM EST | 43 | $54.37 |
| Jun 13, 2022 7:59 PM EST | 33 | $54.37 |
| Jun 13, 2022 7:59 PM EST | 2 | $54.37 |
Dr. Reddy's Laboratories Limited (RDY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000177/0001575872-20-000177-index.htm |
| 2019-12-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1135951/000083423719000385/0000834237-19-000385-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1135951/000083423720008256/0000834237-20-008256-index.htm |
| 2020-04-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1135951/000083423720009337/0000834237-20-009337-index.htm |
| 2019-09-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1135951/000119312519240412/0001193125-19-240412-index.htm |
| 2020-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1135951/000119312520034275/0001193125-20-034275-index.htm |
| 2019-08-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000231/0001575872-19-000231-index.htm |
| 2019-09-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000242/0001575872-19-000242-index.htm |
| 2019-09-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000246/0001575872-19-000246-index.htm |
| 2019-09-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000250/0001575872-19-000250-index.htm |
| 2019-09-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000254/0001575872-19-000254-index.htm |
| 2019-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000257/0001575872-19-000257-index.htm |
| 2019-09-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000261/0001575872-19-000261-index.htm |
| 2019-09-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000263/0001575872-19-000263-index.htm |
| 2019-10-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000268/0001575872-19-000268-index.htm |
| 2019-10-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000277/0001575872-19-000277-index.htm |
| 2019-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000283/0001575872-19-000283-index.htm |
| 2019-10-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000287/0001575872-19-000287-index.htm |
| 2019-11-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000291/0001575872-19-000291-index.htm |
| 2019-11-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000293/0001575872-19-000293-index.htm |
| 2019-11-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000295/0001575872-19-000295-index.htm |
| 2019-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000297/0001575872-19-000297-index.htm |
| 2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000302/0001575872-19-000302-index.htm |
| 2019-11-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000314/0001575872-19-000314-index.htm |
| 2019-11-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000316/0001575872-19-000316-index.htm |
| 2019-11-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000318/0001575872-19-000318-index.htm |
| 2019-12-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000320/0001575872-19-000320-index.htm |
| 2019-12-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000325/0001575872-19-000325-index.htm |
| 2019-12-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000327/0001575872-19-000327-index.htm |
| 2019-12-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000331/0001575872-19-000331-index.htm |
| 2019-12-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000339/0001575872-19-000339-index.htm |
| 2019-12-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000341/0001575872-19-000341-index.htm |
| 2019-12-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000345/0001575872-19-000345-index.htm |
| 2019-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587219000347/0001575872-19-000347-index.htm |
| 2020-01-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000004/0001575872-20-000004-index.htm |
| 2020-01-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000006/0001575872-20-000006-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000008/0001575872-20-000008-index.htm |
| 2020-01-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000014/0001575872-20-000014-index.htm |
| 2020-01-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000016/0001575872-20-000016-index.htm |
| 2020-01-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000018/0001575872-20-000018-index.htm |
| 2020-01-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000020/0001575872-20-000020-index.htm |
| 2020-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000025/0001575872-20-000025-index.htm |
| 2020-02-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000027/0001575872-20-000027-index.htm |
| 2020-02-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000031/0001575872-20-000031-index.htm |
| 2020-02-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000033/0001575872-20-000033-index.htm |
| 2020-02-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000035/0001575872-20-000035-index.htm |
| 2020-02-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000039/0001575872-20-000039-index.htm |
| 2020-02-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000043/0001575872-20-000043-index.htm |
| 2020-03-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000047/0001575872-20-000047-index.htm |
| 2020-03-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000049/0001575872-20-000049-index.htm |
| 2020-03-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000051/0001575872-20-000051-index.htm |
| 2020-03-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000055/0001575872-20-000055-index.htm |
| 2020-03-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000060/0001575872-20-000060-index.htm |
| 2020-03-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000064/0001575872-20-000064-index.htm |
| 2020-03-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000066/0001575872-20-000066-index.htm |
| 2020-03-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000068/0001575872-20-000068-index.htm |
| 2020-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000072/0001575872-20-000072-index.htm |
| 2020-04-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000082/0001575872-20-000082-index.htm |
| 2020-04-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000084/0001575872-20-000084-index.htm |
| 2020-04-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000090/0001575872-20-000090-index.htm |
| 2020-04-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000092/0001575872-20-000092-index.htm |
| 2020-05-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000094/0001575872-20-000094-index.htm |
| 2020-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000100/0001575872-20-000100-index.htm |
| 2020-05-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000103/0001575872-20-000103-index.htm |
| 2020-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000105/0001575872-20-000105-index.htm |
| 2020-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000107/0001575872-20-000107-index.htm |
| 2020-05-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000111/0001575872-20-000111-index.htm |
| 2020-05-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000121/0001575872-20-000121-index.htm |
| 2020-05-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000125/0001575872-20-000125-index.htm |
| 2020-05-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000127/0001575872-20-000127-index.htm |
| 2020-05-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000129/0001575872-20-000129-index.htm |
| 2020-05-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000131/0001575872-20-000131-index.htm |
| 2020-06-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000135/0001575872-20-000135-index.htm |
| 2020-06-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000139/0001575872-20-000139-index.htm |
| 2020-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000141/0001575872-20-000141-index.htm |
| 2020-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000143/0001575872-20-000143-index.htm |
| 2020-06-15 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000145/0001575872-20-000145-index.htm |
| 2020-06-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000147/0001575872-20-000147-index.htm |
| 2020-06-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000155/0001575872-20-000155-index.htm |
| 2020-06-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000157/0001575872-20-000157-index.htm |
| 2020-06-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000159/0001575872-20-000159-index.htm |
| 2020-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000161/0001575872-20-000161-index.htm |
| 2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000165/0001575872-20-000165-index.htm |
| 2020-07-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000177/0001575872-20-000177-index.htm |
| 2020-07-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000179/0001575872-20-000179-index.htm |
| 2020-07-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000181/0001575872-20-000181-index.htm |
| 2020-07-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000187/0001575872-20-000187-index.htm |
| 2020-07-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000192/0001575872-20-000192-index.htm |
| 2020-07-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000196/0001575872-20-000196-index.htm |
| 2020-07-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000202/0001575872-20-000202-index.htm |
| 2020-07-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000204/0001575872-20-000204-index.htm |
| 2020-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000212/0001575872-20-000212-index.htm |
| 2020-08-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000218/0001575872-20-000218-index.htm |
| 2020-08-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000222/0001575872-20-000222-index.htm |
| 2020-08-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000230/0001575872-20-000230-index.htm |
| 2020-08-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000232/0001575872-20-000232-index.htm |
| 2020-08-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000237/0001575872-20-000237-index.htm |
| 2020-08-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000245/0001575872-20-000245-index.htm |
| 2020-09-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000247/0001575872-20-000247-index.htm |
| 2020-09-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000249/0001575872-20-000249-index.htm |
| 2020-09-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000251/0001575872-20-000251-index.htm |
| 2020-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000255/0001575872-20-000255-index.htm |
| 2020-09-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000257/0001575872-20-000257-index.htm |
| 2020-09-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000262/0001575872-20-000262-index.htm |
| 2020-09-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000264/0001575872-20-000264-index.htm |
| 2020-09-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000266/0001575872-20-000266-index.htm |
| 2020-09-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000268/0001575872-20-000268-index.htm |
| 2020-10-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000270/0001575872-20-000270-index.htm |
| 2020-10-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000272/0001575872-20-000272-index.htm |
| 2020-10-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000274/0001575872-20-000274-index.htm |
| 2020-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000276/0001575872-20-000276-index.htm |
| 2020-10-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000278/0001575872-20-000278-index.htm |
| 2020-10-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000280/0001575872-20-000280-index.htm |
| 2020-10-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000282/0001575872-20-000282-index.htm |
| 2020-10-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000288/0001575872-20-000288-index.htm |
| 2020-10-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000290/0001575872-20-000290-index.htm |
| 2020-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000292/0001575872-20-000292-index.htm |
| 2020-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000294/0001575872-20-000294-index.htm |
| 2020-10-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1135951/000157587220000296/0001575872-20-000296-index.htm |